{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:11:40Z","timestamp":1791310300132,"version":"4.3.1"},"reference-count":34,"publisher":"Impact Journals, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,1,19]]},"DOI":"10.18632\/oncotarget.5436","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T21:42:05Z","timestamp":1445895725000},"page":"2721-2733","source":"Crossref","is-referenced-by-count":17,"title":["The <i>BIM<\/i> deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Tun Kiat","family":"Ko","sequence":"first","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui San","family":"Chin","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T.H.","family":"Chuah","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"},{"name":"Department of Haematology, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"},{"name":"Present address: Singapore Institute for Clinical Sciences (SICS), Brenner Centre for Molecular Medicine, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King-Pan","family":"Ng","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"},{"name":"Present address: Cancer Science Institute of Singapore, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Lin","family":"Khaw","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia"},{"name":"Royal Children's Hospital, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.S.","family":"Huang","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia"},{"name":"Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia"},{"name":"Royal Children's Hospital, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Tiong","family":"Ong","sequence":"additional","affiliation":[{"name":"Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore"},{"name":"Department of Haematology, Singapore General Hospital, Singapore"},{"name":"Department of Medical Oncology, National Cancer Centre, Singapore"},{"name":"Department of Medicine, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,10,28]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Nagarajan","year":"2012","journal-title":"Nature Medicine"},{"key":"2","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Hungerford","year":"1960","journal-title":"Science"},{"key":"3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Grosveld","year":"1984","journal-title":"Cell"},{"key":"4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0092-8674(95)90277-5","article-title":"Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene","volume":"82","author":"Witte","year":"1995","journal-title":"Cell"},{"key":"5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Witte","year":"1990","journal-title":"Science"},{"key":"6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0092-8674(91)90521-Y","article-title":"The BCR gene encodes a novel serine\/threonine kinase activity within a single exon","volume":"67","author":"Witte","year":"1991","journal-title":"Cell"},{"key":"7","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.1128\/MCB.13.12.7587","article-title":"A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins","volume":"13","author":"Wang","year":"1993","journal-title":"Molecular and Cellular Biology"},{"key":"8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Schlessinger","year":"1993","journal-title":"Cell"},{"key":"9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nature Reviews Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Strasser","year":"2008","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"11","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Strasser","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"12","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","article-title":"Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds","volume":"65","author":"Valent","year":"2005","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","article-title":"Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors","volume":"24","author":"Inaba","year":"2004","journal-title":"Molecular and Cellular Biology"},{"key":"14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Bhatia","year":"2004","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Talpaz","year":"2003","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood.V98.13.3864","article-title":"Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells","volume":"98","author":"Melo","year":"2001","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Melo","year":"2003","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2003-04-1074","article-title":"efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines","volume":"103","author":"Druker","year":"2004","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Sawyers","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Capdeville","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"22","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1074\/jbc.M402290200","article-title":"A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2","volume":"279","author":"Grant","year":"2004","journal-title":"J Biol Chem"},{"key":"23","first-page":"188","article-title":"Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells","volume":"62","author":"Grant","year":"2002","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm1127","article-title":"Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells","volume":"10","author":"Gewirtz","year":"2004","journal-title":"Nature Medicine"},{"key":"25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Sawyers","year":"2002","journal-title":"Cancer Cell"},{"key":"27","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Hughes","year":"2002","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Preudhomme","year":"2002","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"35631","DOI":"10.1074\/jbc.M005401200","article-title":"c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines","volume":"275","author":"Van Etten","year":"2000","journal-title":"J Biol Chem"},{"key":"30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Sawyers","year":"2004","journal-title":"Science"},{"key":"31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Cavazza","year":"2005","journal-title":"Cancer Cell"},{"key":"32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Sawyers","year":"2008","journal-title":"Cancer Cell"},{"key":"33","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1128\/MCB.00477-08","article-title":"Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance","volume":"28","author":"Ong","year":"2008","journal-title":"Molecular and Cellular Biology"},{"key":"34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.onc.1209901","article-title":"A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation","volume":"26","author":"Ong","year":"2007","journal-title":"Oncogene"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T16:43:30Z","timestamp":1589215410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,28]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,1,19]]}},"alternative-id":["5436","26517680"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5436","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,28]]}}}